All In MedTech

Device Trial Radar · NCT06453187

A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers

Multicenter, Prospective, Randomized, Controlled Platform Trial Assessing Clinical Utility of Cellular, Acellular and Matrix-like Products (CAMPs) and Standard of Care vs SOC Alone in Hard-to-Heal Diabetic Foot and Venous Leg Ulcers.

Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

350

Planned (sponsor's estimate)

Start

Nov 18, 2024

Primary completion

Dec 31, 2026

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Integra LifeSciences CorporationPublic (IART)
Sponsor type
Industry
Collaborators
SerenaGroup, Inc.
First posted
Jun 11, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine how well multiple CAMPs (Cellular, Acellular and Matrix-Like Products) and Standard of Care work when compared to Standard of Care alone in achieving complete closure of hard-to-heal diabetic foot and venous leg ulcers.

Conditions

  • Diabetic Foot Ulcer
  • Venous Leg Ulcer

Interventions

  • Urinary Bladder Matrix (UBM) sheet device for Venous Leg UlcersDevice

    Application of Urinary Bladder Matrix (UBM) sheet device, a porcine-derived extracellular matrix scaffold, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

  • Urinary Bladder Matrix (UBM) sheet device for Diabetic Foot UlcersDevice

    Application of Urinary Bladder Matrix (UBM) sheet device, a porcine-derived extracellular matrix scaffold, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

  • AmnioExcel Plus for Venous Leg UlcersDevice

    Application of AmnioExcel Plus, a tri-layer (amnion-chorion-amnion) dehydrated human placental membrane allograft, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

  • AmnioExcel Plus for Diabetic Foot UlcersDevice

    Application of AmnioExcel Plus, a tri-layer (amnion-chorion-amnion) dehydrated human placental membrane allograft, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

  • Standard of CareProcedure

    Participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of complete wound closure for target ulcerTime frame: 1-12 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Angel City Research

    Los Angeles, California

  • Center for Clinical Research

    San Francisco, California

  • ILD Research Center

    Vista, California

10 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.